CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • BVXV Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit
  • 6-K Filing

Biondvax Pharmaceuticals (BVXV) 6-KBiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Business Update

Filed: 24 Nov 21, 3:06pm
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 6-K Current report (foreign)
    • 99.1 BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Business Update
    BVXV similar filings
    • 22 Dec 21 Report of Foreign Private Issuer
    • 13 Dec 21 Report of Foreign Private Issuer
    • 2 Dec 21 BiondVax announces Third Quarter 2021 Financial Results and Provides Business Update
    • 24 Nov 21 BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Business Update
    • 22 Nov 21 Report of Foreign Private Issuer
    • 12 Nov 21 Report of Foreign Private Issuer
    • 25 Oct 21 BiondVax advances its growth strategy towards a new pipeline based on innovative VHH antibodies
    Filing view
    Share this filing

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

    Under the Securities Exchange Act of 1934

     

    For the Month of November 2021

     

    Commission File Number: 001-37353

     

    BIONDVAX PHARMACEUTICALS LTD.

    (Translation of registrant’s name into English)

     

    Jerusalem BioPark, 2nd Floor

    Hadassah Ein Kerem Campus

    Jeusalem, Israel

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒     Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

     

     

     

    On November 24, 2021, BiondVax Pharmaceuticals Ltd. issued a press release announcing notice of its annual general meeting of shareholders and providing a business update. A copy of the press release is filed herewith as Exhibit 99.1.

     

    Exhibit Index

    Exhibit No. Description
       
    99.1 Press release, dated November 24, 2021.

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     BiondVax Pharmaceuticals Ltd.
       
    Date: November 24, 2021By:/s/ Amir Reichman
      Amir Reichman
      Chief Executive Officer

     

     

     

     

     

    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn